ROS1 and glioblastoma: We identified druggable fusions, particularly CEP85L‐ROS1 and GOPC‐ROS1, that bound crizotinib analogues (e.g., entrectinib and larotrectinib) in TCGA GBM patients, as reported previously by Davare et al.